2ND NEOPLASMS AFTER ADJUVANT CHEMOTHERAPY FOR OPERABLE BREAST-CANCER
2ND NEOPLASMS AFTER ADJUVANT CHEMOTHERAPY FOR OPERABLE BREAST-CANCER
复制标题
DOI：
10.1097/00000421-198606000-00018
复制
发表时间：
1986-06-01
影响因子：
2.6
通讯作者：
BLUMENSCHEIN, GR
中科院分区：
文献类型：
--
作者：
HERRING, MK;BUZDAR, AU;BLUMENSCHEIN, GR
1974 年至 1982 年间，德克萨斯大学 MD 安德森医院和休斯顿肿瘤研究所对 797 名可手术乳腺癌患者进行了三项辅助化疗试验，包括氟尿嘧啶、阿霉素和环磷酰胺 (FAC)。对这组患者中第二原发性恶性肿瘤的发生率进行了评估，并与历史对照组（由 II 期和 III 期疾病患者（n = 186）且术后未接受辅助化疗的患者进行比较）。 54% (n = 433) 的化疗患者和 96% (n = 178) 的对照组接受了放射治疗。治疗组和对照组患者的中位年龄分别为 49.6 岁和 55 岁。 10 名接受化疗的患者和 9 名对照患者中出现了第二种肿瘤；根据精算曲线，治疗开始后 5 年的死亡率分别为 1.9% 和 5.0%。 FAC 治疗组的中位潜伏期为 17.5 个月，而对照组的中位潜伏期为 13 个月。两个治疗组各出现两例白血病。与历史对照组相比，接受化疗的患者第二恶性肿瘤的发生率没有增加。
Between 1974 and 1982, 797 patients who had operable breast cancer were treated at the University of Texas M. D. Anderson Hospital and Tumor Institute at Houston with three adjuvant chemotherapy trials consisting of fluorouracil, doxorubicin, and cyclophosphamide (FAC). The incidence of second primary malignant tumors in this group of patients was evaluated and compared with that in a historical control group of patients who had stages II and III disease (n = 186) and who did not receive adjuvant chemotherapy following surgery. Radiotherapy was given to 54% (n = 433) of the chemotherapy-treated patients and to 96% (n = 178) of the controls. The median age of the patients was 49.6 and 55 years for the treated and control groups, respectively. Second neoplasms developed in 10 chemotherapy-treated patients and in nine control patients; rates at 5 years from initiation of therapy based on actuarial curves were 1.9 and 5.0%, respectively. These second tumors developed after a median latency period of 17.5 months for the FAC-treated group and 13 months for the controls. Two cases of leukemia developed in each of the two treatment groups. The rate of second malignancy in the chemotherapy-treated patients was not increased compared with that in the historical controls.